Unusual benign and malignant chondroid tumors of bone.A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas

Lichtenstein, Louis; Bernstein, Donald P.

doi:10.1002/1097-0142(195911/12)12:6<1142::aid-cncr2820120610>3.0.co;2-d

Cited by 380 publications

(150 citation statements)

References 4 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Although general trends and features of the clinical behavior of mesenchymal chondrosarcoma have been suggested in prior studies [1,14,15,17,18], no large series have been available to verify these descriptions as a result of the rarity of this disease. To date, the largest study on mesenchymal chondrosarcoma was performed by Nakashima et al [18], which presented 111 new patients with mesenchymal chondrosarcoma and reviewed 132 previously reported patients.…”

Section: Discussionmentioning

confidence: 94%

“…Mesenchymal chondrosarcoma is a rare malignancy that represents 2% to 9% of all chondrosarcomas [17]. It arises most commonly in the second and third decades of life [1,3,8,14].…”

Section: Introductionmentioning

confidence: 99%

“…In comparison to conventional chondrosarcoma, which has a 10-year overall survival rate of 60% to 70% [6,7,9], the mesenchymal subtype is believed to portend a worse prognosis [2,14,17]. The 10-year survivorship of mesenchymal chondrosarcoma has been previously reported as ranging from 20% to 67% [3,8,11,14,15,17,18,21] with cohorts comprised of head and neck tumors or of pediatric patients representing the upper end of this spectrum [4,16,23]. The disease recently was reported to have a median event-free survival of 57 months [25].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of extraskeletal tumors than conventional chondrosarcoma. However, these investigations have been small heterogeneous cohorts, limiting analysis of prognostic factors. Questions/purposes (1) What is the 5-and 10-year survival rate of patients diagnosed with mesenchymal chondrosarcoma? (2) What is the effect of demographic and tumor characteristics on survival in patients with mesenchymal chondrosarcoma? Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to identify all patients diagnosed with mesenchymal chondrosarcoma from 1973 to 2011. SEER reports survival data on over 8.2 million patients with cancer and has attained 98% completeness in reporting. Using variables within the database, this study designated each patient's tumor as skeletal or extraskeletal and cranial, axial, or appendicular, respectively. Overall survival (OS) was determined for the entire series as well as each group. Median survival was calculated using KaplanMeier methods. Cox proportional hazards regression was used to determine whether demographic and tumor variables affected survival. Two hundred five patients with mesenchymal chondrosarcoma were identified, including 82 (40%) skeletal and 123 (60%) extraskeletal. Results OS for the entire series was 51% (95% confidence interval [CI], 43%-58%) and 43% (95% CI, 35%-51%) at 5 and 10 years, respectively. No difference in OS was detected between extraskeletal and skeletal tumors. KaplanMeier analyses showed OS was worse for tumors in axial locations compared with appendicular and cranial locations. Appendicular tumors demonstrated an OS of 50% (95% CI, 36%-63%) at 5 years and 39% (95% CI, 26%-52%) at 10 years. OS for axial tumors was 37% (95% CI, 25%-49%) and 31% (95% CI, 20%-43%), whereas it was 74% (95% CI, 59%-84%) and 67% (95% CI, 50%-79%) for cranial tumors at 5 and 10 years, respectively. When controlling for age, sex, tumor origin, and tumor location, the presence of metastasis (hazard ratio [HR], 12.38; 95% CI, 5.75-26.65; p \ 0.001) and 1-cm size increase (HR, 1.16; 95% CI, 1.09-1.23; p \ 0.001) were both independently associated with an increased risk of death. Tumor location showed different behaviors depending on patient age. In comparison to cranial tumors at age 20 years, the HR was 5.56 (95% CI, 1.47-21.05; p = 0.01) for axial tumors and 6.26 (95% CI, 1.54-25.42; p = 0.01) for appendicular tumors. At age 60 years, those ratios were 0.10 (95% CI, 0.02-0.55; p = 0.01) and 0.14 (95% CI, 0.04-0.58; p = 0.01), respectively. Conclusions Our data suggest that extraskeletal tumors are more common than previously reported; however, this factor does not have clear prognostic value. Presence of metastatic disease and increased tumor size are the main Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, paten...

show abstract

Section: Discussionmentioning

confidence: 94%

“…Mesenchymal chondrosarcoma is a rare malignancy that represents 2% to 9% of all chondrosarcomas [17]. It arises most commonly in the second and third decades of life [1,3,8,14].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…The tumor mass, which involved the ribs, was decalcified, routinely embedded in paraffin, and cut at 5 µm. The tumor mass was sectioned as Mesenchymal chondrosarcoma in human beings, first described in 1959 [4], is a rare malignant tumor of the soft tissues and bones as defined by the coexistence of nests of well-defined cartilaginous tissue within a proliferation of primitive mesenchymal cells. A similar neoplasm in dogs was also diagnosed as mesenchymal chondrosarcoma and was recognized as a separate entity in 1984 [8].…”

mentioning

confidence: 99%

Canine Mesenchymal Chondrosarcoma of the Ribs.

Madarame¹,

Itoh

Yoshida³

et al. 1998

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The tumor of the thoracic cavity, which arose from the ribs, was diagnosed as mesenchymal chondrosarcoma. No distant metastasis was observed. Histologically, the tumor was characterized by the nests of well-defined cartilaginous tissue within a proliferation of primitive mesenchymal cells. Additionally, the deformed blood vessels compressed by the proliferating mesenchymal cells exhibited clear stag-horn appearance. Immunohistochemically, most neoplastic cells that formed multifocal cartilaginous islands were positive for S-100 protein, while the surrounding mesenchymal cells were negative. This is the first report of canine mesenchymal chondrosarcoma of the ribs. -KEY WORDS: canine, mesenchymal chondrosarcoma, rib.

show abstract

“…Although mesenchymal chondrosarcoma was first described in 1959 [5], Dahlin et al [6] first used the word "mesenchymal chondrosarcoma" and reported a first case of intracranial mesenchymal chondrosarcoma in 1962. Bingaman et al reviewed 26 case reports of intracranial extraskeletal mesenchymal chondrosarcomas reported in the English language literature from 1962 to 1999 [7].…”

Section: Discussionmentioning

confidence: 99%

Primary Intracranial Mesenchymal Chondrosarcoma: A Case Report

Cho¹

2018

J Med Cases

View full text Add to dashboard Cite

Mesenchymal chondrosarcoma is a rare malignancy characterized by a biphasic pattern of small undifferentiated round cells intermixed with island of well-differentiated cartilaginous matrix. Although this type of tumor exhibits widespread distribution in the body, intracranial mesenchymal chondrosarcoma is rare. Radical excision of intracranial mesenchymal chondrosarcoma is important for obtaining a positive prognosis but the effectiveness of chemotherapy and radiotherapy remains uncertain. An 18-year-old patient presented with generalized seizure with magnetic resonance imaging showing a large dura-attached solid mass in the frontal convexity, which was presumptively diagnosed as a meningioma. Gross total resection of tumor was achieved without postoperative deficit. The final histological diagnosis was extra-skeletal mesenchymal chondrosarcoma, grade I. There was no adjuvant treatment after surgery. Five years after surgery, the prognosis was good after gross total resection only; however, long-term follow-up is necessary in the future.

show abstract

Unusual benign and malignant chondroid tumors of bone.A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas

Cited by 380 publications

References 4 publications

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Canine Mesenchymal Chondrosarcoma of the Ribs.

Primary Intracranial Mesenchymal Chondrosarcoma: A Case Report

Contact Info

Product

Resources

About